Compass Pathways Gains 25% After FDA Rolling NDA Review and Priority Voucher
Compass Pathways won rolling FDA NDA review and a Commissioner’s National Priority Voucher for COMP360 psilocybin therapy, potentially cutting approval timelines. It partnered with Osmind’s 1,000+ psychiatry clinics for scalable real-world delivery and leveraged FDA ultra-fast review signals plus a White House Executive Order to fuel a 25% stock rally.
1. Regulatory Milestones Achieved
Compass Pathways secured a rolling New Drug Application review from the FDA for its COMP360 synthetic psilocybin therapy and was awarded a Commissioner’s National Priority Voucher, a designation designed to accelerate regulatory review timelines for treatments addressing urgent unmet needs.
2. Commercialization Partnership Launched
The company announced a strategic collaboration with Osmind, tapping into a network of over 1,000 psychiatry clinics to establish scalable, patient-centered delivery models for COMP360, focusing on real-world readiness, safety protocols and effective clinic-based administration upon approval.
3. Policy Support and Market Reaction
Following a White House Executive Order and FDA signals on ultra-fast review pathways for psychedelic therapies, Compass Pathways’ stock rallied more than 25%, reflecting investor confidence in its positioning at the forefront of treatment-resistant depression innovation.